$7.58
▲ +0.1% Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
Emergent Gets $52.7 Million Contract Modification From US Government
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
Overview
52-week range
$5.62
$14
23% of range
Avg surprise (last 2)
+103.2%
Avg reaction (last 1)
-1.0%
0% positive
Latest IV / EM
69%
EM ±15.8% · $8 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $0.07 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $0.91 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.16 | $-0.26 | +161.5% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $0.71 | $0.49 | +44.9% | — | -1.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $2.06 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-5.38 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.17 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-5.08 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-5.16 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | — | $0.16 |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $294M | $255M |
| Cost of revenue | $72M | — | $86M | $67M | $88M | — | $123M | $296M |
| Gross profit | — | — | — | — | — | — | $161M | $-48M |
| Operating income | $10M | — | $76M | $2M | $50M | — | $64M | $-204M |
| Net income | $7M | — | $51M | $-12M | $68M | — | $115M | $-283M |
| EPS (diluted) | $0.07 | — | $0.91 | $-0.22 | $1.19 | — | $2.06 | $-5.38 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $160M | $205M | $246M | $267M | $149M | $100M | $150M | $70M |
| Inventory | $328M | $343M | $356M | $339M | $314M | $312M | $323M | $318M |
| Total current assets | $638M | $662M | $787M | $720M | $707M | $599M | $661M | $654M |
| Total assets | $1.32B | $1.32B | $1.46B | $1.42B | $1.43B | $1.39B | $1.48B | $1.51B |
| Long-term debt | $574M | $572M | $663M | $668M | $666M | $664M | $662M | $447M |
| Total liabilities | $797M | $796M | $878M | $881M | $873M | $907M | $969M | $1.13B |
| Total equity | $523M | $523M | $582M | $536M | $553M | $483M | $508M | $386M |